Lind S E, Cashavelly B, Fuller A F
Hematology-Oncology Unit, Massachusetts General Hospital, Boston 02114.
Surg Gynecol Obstet. 1988 Jun;166(6):519-22.
The treatment of malignant ascites is a difficult task that faces the physician who is treating patients with advanced carcinoma. We describe the clinical course of three patients with malignant ascites caused by advanced carcinoma of the ovary who were treated with cisplatin-based intraperitoneal chemotherapy. In all three patients, there was resolution of the ascites with relief of symptoms caused by abdominal distention. Although one patient had a fall in the serum level of CA 125 (the antigen marker of carcinoma of the ovary) with repeated courses of intraperitoneal therapy, there was little reduction in the bulky abdominal tumors. Even though intraperitoneal chemotherapy, as currently administered, does not appear to effect a significant reduction in tumor in women with bulky carcinoma of the ovary, it may be of benefit in improving the quality of life. Larger numbers of patients should be studied to better assess the role of this method of treatment in the palliative cure of patients with symptomatic malignant ascites.
恶性腹水的治疗对于治疗晚期癌症患者的医生而言是一项艰巨任务。我们描述了3例由晚期卵巢癌引起的恶性腹水患者接受以顺铂为基础的腹腔内化疗的临床过程。在所有3例患者中,腹水均消退,腹胀引起的症状得到缓解。尽管1例患者在重复进行腹腔内治疗疗程后血清CA 125(卵巢癌抗原标志物)水平有所下降,但腹部巨大肿瘤几乎没有缩小。尽管目前实施的腹腔内化疗似乎并未使患有巨大卵巢癌的女性肿瘤显著缩小,但它可能有助于改善生活质量。应该研究更多患者,以更好地评估这种治疗方法在对症治疗恶性腹水患者的姑息治疗中的作用。